The GLP-1 Agonist Family: A Tale of Two Timelines By 2026, the world of GLP-1 receptor agonists has become quite sprawling, but for most people pursuing medically-supervised weight loss, two names stand out: Semaglutide and Tirzepatide
Tirzepatide is not indicated for type 1 diabetes and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
or Imply FDA approval, clearance, or clinical evaluation or otherwise misrepresent the source or regulatory status of the product Compounding Practices Organizations involved in dispensing or coordinating compounded medications should evaluate whether compounding is performed pursuant to patient-specific prescriptions and the activity aligns with federal compounding requirements
Whether it's a wedding party prepping for the big day, a corporate wellness event, or friends recovering together after celebrating, group treatments offer both convenience and cost savings
They may participate in group, individual, family, and experiential therapies, and they also have access to medication management services, detoxification services, and 24/7 medical care
Safety Profile The safety data from TRIUMPH-4 were consistent with the known class effects of incretin receptor agonists, with no unexpected signals emerging at either dose
